Peregrine Pharmaceuticals reported $450.43M in Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Agenus AGEN:US USD 413.56M 15.46M
Amgen AMGN:US USD 65.12B 1.42B
AstraZeneca AZN:LN USD 96.48B 2.3B
Biocryst Pharmaceuticals BCRX:US USD 550M 8.59M
Celldex Therapeutics CLDX:US USD 352.73M 16.49M
GlaxoSmithKline GSK:LN GBP 60.15B 167M
Immunogen IMGN:US USD 348.94M 9.86M
Intrexon XON:US USD 215.98M 43.27M
Karyopharm Therapeutics KPTI:US USD 358.17M 126.94M
Macrogenics MGNX:US USD 280.47M 85.12M
Mannkind MNKD:US USD 295.28M 1.44M
Minerva Neurosciences NERV:US USD 55.09M 4.67M
Newlink Genetics NLNK:US USD 72.29M 6.92M
Novartis NOVN:VX USD 117.45B 1.01B
Novavax NVAX:US USD 2.26B 8.76M
Peregrine Pharmaceuticals PPHM:US USD 450.43M 8.58M
Repligen RGEN:US USD 2.52B 62.13M
Roche Holding ROG:VX 88.15B 1.42B
Xencor XNCR:US USD 846.27M 11M